相关实验视频
Updated: Sep 11, 2025

08:30
Use of a Hanging Weight System for Coronary Artery Occlusion in Mice
Published on: April 19, 2011
21.8K
针对腺受体的合成小分子接体:是否有可能导致缺血性心脏病?
Qi Xu1, Yaw Nana Opoku1, Kalwant S Authi2
1Institute of Pharmaceutical Science, King's College London, Stamford Street, London SE1 9NH, UK.
Cells
|August 13, 2025
概括
腺素受体 (AR) 和它们的合成连接体显示出对缺血性心脏病 (IHD) 的治疗潜力. 需要进一步的研究来开发有效和安全的AR向药物用于临床使用.
科学领域:
- 心血管生物学 心血管生物学
- 药理学 药理学是指药理学的学科.
- 分子医学是分子医学.
背景情况:
- 缺血性心脏病 (IHD) 仍然是全球主要的死亡原因,尽管治疗进展.
- 目前针对IHD进展的治疗策略对全球发病率的影响有限.
- 腺素受体 (ARs) 是心血管研究的关键目标.
研究的目的:
- 审查ARs的细胞生物学和合成AR配体对IHD的治疗潜力.
- 要突出AR合成配体在临床前或临床研究中已证明有效性的进展.
- 为IHD提供AR向治疗的最新视角.
主要方法:
- 审查关于腺受体及其合成连接体的现有文献.
- 分析临床前和临床研究数据,以确定AR连接剂在IHD中的疗效.
- 检查与IHD中的AR功能相关的细胞生物学方面.
主要成果:
- 几种合成的小分子AR配体显示出作为IHD的新治疗候选者的希望.
- 证据支持临床上有效的AR向剂的存在.
- 大多数AR配体药物原型都处于临床前阶段,缺乏大规模试验.
结论:
- AR合成配体代表了IHD的新兴治疗领域.
- 未来的努力应专注于提高连接剂的疗效,选择性和安全性.
- 开发强大的临床前测试平台对于为临床研究提供信息至关重要.
相关概念视频
Adrenergic Agonists: Direct-Acting Agents
1.7K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.7K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.0K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
508
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
508
Heart Failure Drugs: Inotropic Agents
722
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
722
Adrenergic Agonists: Indirect-Acting Agents
1.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.8K
Antianginal Drugs: Nitrates and β-Blockers
753
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
753

